Athersys Stock News

Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal, Intensive Care Medicine.  MUST-ARD

The stock price of Athersys Inc (NASDAQ: ATHX) increased by over 15% pre-market today. This is why it happened.

Livingston Group Asset Management CO operating as Southport Capital Management lowered its position in Athersys, Inc. (NASDAQ:ATHX) by 51.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,380 shares of the biopharmaceutical companys stock after selling 41,770 shares during the period. Livingston Group Asset Management []

During the last session, Athersys Inc. (NASDAQ:ATHX)s traded shares were 1.75 million, with the beta value of the company hitting -1.60. At the end of the trading day, the stocks price was $1.04, reflecting an intraday gain of 1.96% or $0.02. The 52-week high for the ATHX share is $3.03, that puts it down -191.35 Athersys Inc. (NASDAQ: ATHX) Is Down -11.86% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

Amalgamated Bank raised its holdings in Athersys, Inc. (NASDAQ:ATHX) by 36.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,608 shares of the biopharmaceutical companys stock after purchasing an additional 9,689 shares during the quarter. Amalgamated Banks holdings in Athersys were worth $53,000 []

I covered Athersys' ischemic stroke trial earlier.

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athersys, Inc. (NASDAQ:ATHX) was the recipient of a significant increase in short interest in the month of October. As of October 29th, there was short interest totalling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is presently […]

Athersys, Inc. (NASDAQ:ATHX) was the target of a large increase in short interest in October. As of October 29th, there was short interest totalling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Currently, 7.9% of the shares of the stock are short sold. Based on an average daily volume […]

Green Alpha Advisors LLC grew its position in Athersys, Inc. (NASDAQ:ATHX) by 7.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 191,242 shares of the biopharmaceutical companys stock after acquiring an additional 13,434 shares during the quarter. Green Alpha []

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Bank of America lowered shares of Athersys (NASDAQ:ATHX) from a buy rating to a neutral rating in a research note issued to investors on Friday, Price Targets.com reports. The firm currently has $1.25 price target on the biopharmaceutical companys stock. Separately, Zacks Investment Research lowered shares of Athersys from a buy rating to a hold []

Athersys, Inc. (NASDAQ:ATHX) Director Ismail Kola acquired 85,000 shares of Athersys stock in a transaction that occurred on Friday, November 19th. The stock was acquired at an average cost of $0.96 per share, with a total value of $81,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the []

Athersys Inc. (NASDAQ:ATHX) price on Friday, November 19, fall -17.27% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.93. A look at the stocks price movement, the level at last check in todays session was $1.13, moving within a range at $1.12 and $1.185. The beta value Athersys Inc. (ATHX): At $0.93, Its Worth Your Attention Read More »